Claris Lifesciences Ltd today said its consolidated net profit jumped by 233 percent at Rs 35 crore in Q3 FY2017 as against Rs 15 crore in the corresponding period of last year.
Total consolidated income for Q3FY 2017 grew by 16 percent YoY at Rs 221 crore against Rs 190 crore in the corresponding period of last year, a company statement said here.
During the 9-months period ended December 31, 2016, consolidated net profit was at Rs 96 crore, up by 92 percent against Rs 50 crore PAT in the corresponding period of last year.
The total consolidated income for 9MFY2017 stood at Rs 614 crore against Rs 574 crore in the corresponding period of last year.
The company's speciality injectable business revenues in Q3FY17 stood at Rs 216 crore, delivering a YoY growth of 32 percent. Sales in US market continued to drive the growth of the company in SIB business with improved margins, it said.
On December 15, 2016 company has entered into definitive agreements with Baxter to transfer its injectable business. The company is in process of taking various regulatory approvals for the same.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
